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Background: The present study was aimed to evaluate whether IgG, IgM and IgA antibodies levels detected against a
novel Mycobacterium tuberculosis polyprotein 38 F-64 F (with 38 F being the abbreviation for 38kD-ESAT6-CFP10 and
64 F for Mtb8.4-MPT64-TB16.3-Mtb8) are suitable for diagnosing active tuberculosis, and for monitoring the efficacy of
chemotherapy on TB patients.
Methods: In this study, a total of 371 active TB patients without treatment were selected and categorized into
S+/C+ group (n = 143), S-/C+ group (n = 106) or S-/C- group (n = 122). A series of serum samples were collected from
82 active TB patients who had undergone anti-TB chemotherapy for 0–6 months at one month interval. Humoral
responses (IgG, IgM and IgA) were determined for the novel Mycobacterium tuberculosis polyprotein using indirect
ELISA methods in all of serum samples.
Results: For S+/C+, S-/C+ and S-/C- active tuberculosis patients before anti-TB chemotherapy, the sensitivities of tests
based on IgG were 65.7%, 46.2% and 52.5% respectively; the sensitivities based on IgM were 21.7%, 24.5% and 18.9%;
and the sensitivities based on IgA were 25.2%, 17.9% and 23.8%. By combination of three isotypes, for all active
tuberculosis patients, the test sensitivity increased to 70.4% with the specificity being 91.5%. After anti-TB chemotherapy,
there were no significant differences between groups with different courses of anti-TB chemotherapy.
Conclusions: The novel Mycobacterium tuberculosis polyprotein 38 F-64 F represents potential antigen suitable for
measuring IgG, IgM and IgA antibodies. However, the serodiagnostic test based on the 38 F-64 F polyprotein appears
unsuitable for monitoring the efficacy of chemotherapy.
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Tuberculosis (TB) remains the leading single microbial
illness globally, with one-third of the world’s population
infected with Mycobacterium tuberculosis (M. tubercu-
losis, Mtb) complex. In 2009, there were over 9.4 million
new cases and 1.7 million deaths from M. tuberculosis
[1]. Over 90% of the worldwide burden of tuberculosis
is in low-income and middle-income countries where
the diagnosis of tuberculosis still relies heavily on spu-
tum smear microscopy and chest radiology. There is a
great need for rapid point-of-care tests that can be* Correspondence: zhangheqiu2004@126.com
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the community [2,3].
The identification of the bacillus by microscopic exam-
ination of sputum smear or by culture, however, presents
certain limitations. Around 30-50% of TB patients are
negative in the microscopy examination, and culture re-
quires a long time for the growth of M. tuberculosis,
which maybe lead to delay diagnosis [4,5]. The tubercu-
lin skin test has long been used for the diagnosis of TB.
While this test is the recommended diagnosis test for la-
tent TB infection, it requires standardized application
and interpretation, and a positive result depends on an
adequate immune response [6]. The usefulness of the
IFN-γ-release assays in the diagnosis of active TB re-
mains questionable [7]. Nucleic acid amplification tests,
for example the Xpert MTB/RIF assay, are the mostd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the USA and Europe [8]. However, uses of such tests are
restrictive because this assay requires dedicated and ex-
pensive equipment. The serological test based on the
detection of circulating antibodies against M. tuberculosis-
specific antigens could represent a useful complement to
microscopic examination for screening active tuberculosis
[9]. This method is quite attractive because of its easy ap-
plication, low cost of testing many serum samples in paral-
lel and relatively low invasiveness.
A comprehensive insight to immunoprofiling of anti-
gen specific responses is critical for TB diagnosis and
therapeutic monitoring. Currently, gold standard methods
to diagnosis TB and monitor treatment response in-
clude sputum smear microscopy and culture conversion
after 2 months of TB treatment. But, for patients in
whom such sputum sample is not available, alternative
serological tests are needed. Some results showed that
combined use of different antibody isotypes allow an
increased accuracy in diagnostic of tuberculosis [10],
and the levels of antibody against to some antigens de-
creased together with treatment [11]. On the contrary,
some results showed that combination of IgG with IgA
and/or IgM does not improve its sensitivity, and the
levels of antibody against to other antigens were not as-
sociated with anti-TB treatment [12].
In our previous study, two novel M. tuberculosis poly-
proteins, 38 F (38kD-ESAT6-CFP10) and 64 F (Mtb8.4-
MPT64-TB16.3-Mtb8), were expressed as antigens with
multiepitopes, and evaluated for serodiagnosis of TB.
The novel 38 F-64 F indirect ELISA assay based on
measuring IgG antibody has potential to achieve higher
sensitivity and specificity, and the ROC analysis indi-
cated that the novel 38 F-64 F indirect ELISA assay had
a better overall diagnostic performance [13].
The goals of the present study were to evaluate serum
levels of all of three isotype antibodies, IgG, IgM and
IgA, specific to 38 F-64 F, in patients with active TB and
in BCG-vaccinated healthy individuals, and to assess
whether determination of 38 F-64 F specific antibody re-
sponses could be useful for monitoring the efficacy of
chemotherapy.
Methods
Ethics statement
The study was approved by the ethics committee of the
Beijing Chaoyang District Centre for Disease Control
and Prevention, and Tianjin Haihe Hospital. Written in-
formed consent was obtained from all participants.
Study population
Sera were obtained from patients with active TB and
from normal individuals, as described below. Diagnosis
of active TB was established by the presence of clinicalsymptoms of TB, by chest radiography, and by symp-
tomatic improvement after chemotherapy. Sera were
stored at −70°C until start of testing.
A total of 371 active TB patients at their first visit to
the outpatient clinic without treatment were selected
and categorized into three groups, i.e.
S+/C+: Smear-positive and culture-positive group
(n = 143), with 82 males and 61 females and the age range
from 19 to 67, with a median of 42.
S-/C+: Smear-negative and culture-positive group
(n = 106), with 55 males and 51 females and the age range
from 22 to 70, with a median of 46.
S-/C-: Smear-negative and culture-negative group
(n = 122), with 65 males and 57 females and the age range
from 19 to 78, with a median of 40.
Sputum samples were processed using standard NALC-
NaOH method and smears were examined after Ziehl–
Neelsen staining. Processed samples were inoculated
in MGIT (Mycobacterial growth indicator tube) 960 non-
radiometric automated isolation system (BD, USA) in
accordance with the standard procedure.
To assess whether determination of 38 F-64 F specific
antibody responses could be useful for monitoring the
efficacy of chemotherapy, a series of serum samples were
obtained from 82 active TB patients, which including 30
IgG positive patients, 28 IgA positive patients and 24
IgM positive patients at their first visit to the outpatient
clinic. The diagnosis of active TB in these patients was
based on sputum smear positive and/or sputum culture
positive and/or X-ray clinical findings. All patients had
received combination antituberculosis chemotherapy with
isoniazid and rifampin and pyrazinamide and ethambutol/
streptomycin for 2 months followed by admission isoniazid
and rifampin for 4 months. All patients were HIV sero-
negative and there were no other disease states accom-
panying the TB. A series of serum samples were collected
at one month interval, and divided into seven groups, i.e.,
0 M, 1 M, 2 M, 3 M, 4 M, 5 M and 6 M.
Ninety-four BCG-vaccinated healthy blood donors were
included. Their age ranged from 20 to 55, with a median of
38. The healthy subjects had normal findings on chest
radiogram and no history of close contract with TB pa-
tients and no family history of tuberculosis. These subjects
were apparently normal without HIV infection and other
diseases that might be confused with TB such as pneumo-
nia, fungal infections, lung cancer, etc.
ELISA
Microplates were coated with individual antigens at
5 μg/ml (3 μg/ml 38 F and 2 μg/ml 64 F) in coating buf-
fer (0.05 M carbonate/bicarbonate, pH 9.6) and stored at
4°C overnight. The plates were washed three times with
phosphate-buffered saline (PBS) containing 0.05% Tween
20 (PBST). Two hundred microliters of PBST containing
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plates were sealed and incubated at 37°C for 1 h. The plates
were washed three times. One hundred microliters of
serum diluted 1:10 in PBST containing 1% BSA was added
to each antigen-coated well. The plates were sealed and in-
cubated at 37°C for 30 min and then washed three times.
One hundred microliters of horseradish peroxidase-
conjugated anti-human IgG antibody (Sigma, USA), anti-
human IgM antibody (Bethyl, USA) or anti-human IgA
antibody (Bethyl, USA) was added to each well respect-
ively, and the plates were sealed and incubated at 37°C
for another 30 min. Again, the plates were washed three
times. The bound enzyme was detected by freshly-
prepared tetramethyl benzidine (TMB) substrate. After
20 min incubation in room temperature, the stop solution
(0.1 N sulfuric acid) was added and the optical density was
determined at 450 nm using an automatic microplate
reader (Bio-Rad, USA).
Statistical analysis
Data processing was performed using GraphPad Prism 4.0
(GraphPad Software Inc., San Diego, CA) and SPSS16.0
software package (SPSS Inc., Chicago, IL). The diagnostic
value of the novel 38 F-64 F indirect ELISA assay was eval-
uated by the receiver operating characteristic (ROC) curve
performed with the data from patients with active TB and
94 BCG-vaccinated healthy blood donors. The cutoff value
of 38 F-64 F IgG, IgM and IgA were chosen according
to the ROC analysis. Comparisons between treatment
groups were done by the Mann Whitney test.
Results
IgG, IgM and IgA antibody responses against 38 F-64 F
antigens in active TB without treatment
In our previous study, the novel 38 F-64 F antigens were
confirmed to have potential for higher sensitivity and
specificity based on measuring IgG antibody [13]. Con-
sidering the heterogeneity of the humoral response, in
this study, serum levels of all of three isotype antibodies,
IgG, IgM and IgA, specific to 38 F-64 F were evaluated
in active TB patients at their first visit to the outpatient
clinic without treatment. The data are shown in Table 1
and presented as scattergrams in Figure 1.Table 1 ELISA results of the 38 F-64 F antigens in the serodia
Group S+/C + (n = 143)
IgG IgM IgA
# Pos. (%) 94 (65.7) 31 (21.7) 36 (25.2)
# Pos. for one isotype of antibody 53 4 8
# Combin. Pos. (%) 108 (75.5)
S+/C+: smear-positive and culture-positive active pulmonary TB patients; S-/C+: smear-
and culture-negative active pulmonary TB patients; # Pos. (%): number of positive sera
sera for any of three isotype antibodies (percentage of combination positive sera).Before anti-TB chemotherapy, the sensitivities of the
tests based on IgG were 65.7% (95% CI, 57.3% to 73.5%),
46.2% (95% CI, 36.5% to 56.2%) and 52.5% (95% CI,
43.2% to 61.6%) in S+/C+, S-/C + and S-/C- active tuber-
culosis patients respectively; the sensitivities of the tests
based on IgM were 21.7% (95% CI, 15.2% to 29.3%),
24.5% (95% CI, 16.7% to 33.8%) and 18.9% (95% CI,
12.3% to 26.9%) respectively; and the sensitivities of the
tests based on IgA were 25.2% (95% CI, 18.9% to 33.9%),
17.9% (95% CI, 11.2% to 26.6%) and 23.8% (95% CI,
16.5% to 32.3%) respectively. In S+/C+ group, 53, 4 and
8 sera were IgG-, IgM- and IgA-positive only, respect-
ively, and the number of combination positive sera was
108, which including anyone, any two and all of three
isotype of antibodies positive sera. By combination of all
the three isotype an increased sensitivity from 65.7% to
75.5% was obtained. In S-/C+ group and S-/C- group,
the sensitivity increased from 46.2% to 64.2% and from
52.5% to 69.7% by combination of all the three isotype
respectively.
To evaluate the specificity, all the three isotype anti-
bodies responses were examined in 94 BCG-vaccinated
healthy blood donors. The specificity of the tests based
on IgG, IgM and IgA were 94.7% (95% CI, 88.0% to
98.3%), 92.6% (95% CI, 85.3% to 97.9%) and 95.7% (95% CI,
89.5% to 98.8%) respectively (Figure 1). By combination of
three isotypes, the specificity of the tests decreased slightly
to 91.5% (95% CI, 87.0% to 94.8%). These results are con-
sistent with the results of Uma Devi et al. [14]. In that art-
icle, when IgG was taken individually, the specificity was
100%, when IgG + IgA were taken, the specificity reduced
to 96%, and when IgG+ IgA + IgM were taken, the specifi-
city reduced to 90%.
The serodiagnosis performance of the novel 38 F-64 F
polyprotein on measuring IgG, IgM and IgA antibody
was analyzed with all TB patients and healthy controls
(Figure 1). The area under the ROC curve (AUC) of the
novel 38 F-64 F indirect ELISA assay on measuring IgG,
IgM and IgA antibody were 0.81 (95% CI, 0.75 to 0.85),
0.68 (95% CI, 0.61 to 0.74) and 0.62 (95% CI, 0.56 to 0.69)
respectively. The ROC analysis indicated that the novel
38 F-64 F polyprotein had a better diagnostic performance
on measuring IgG than IgM and IgA.gnosis of active pulmonary TB
S-/C + (n = 106) S-/C- (n = 122)
IgG IgM IgA IgG IgM IgA
49 (46.2) 26 (24.5) 19 (17.9) 64 (52.5) 23 (18.9) 29 (23.8)
29 11 5 39 9 11
68 (64.2) 85 (69.7)
negative and culture-positive active pulmonary TB patients; S-/C-: smear-negative
(percentage of positive sera); # Combin. Pos. (%): number of combination positive
Figure 1 The serodiagnostic performance of the novel 38 F-64 F indirect ELISA assay in active TB patients at their first visit to the
outpatient clinic without treatment. Levels of serum IgG, IgM and IgA against the novel 38 F-64 F polyprotein in S+/C+, S-/C + and S-/C- TB
patients (A1, B1 and C1) and in total TB patient (A2, B2 and C2) were presented as scatter grams respectively. Each bar represents the mean
OD value. The ROC curves of the novel 38 F-64 F indirect ELISA assay based on measuring IgG (A3), IgM (B3) and IgA (C3) were shown and the
areas under the curve (AUC) for IgG, IgM and IgA were 0.81, 0.68 and 0.62 respectively.
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examination to screen for active TB
By combination of all of three isotypes (IgG or IgM
or IgA), a sensitivity of 70.4% (261/371) was obtained
with a specificity of 91.5% (86/94) in all of three
groups of TB patients without treatment. Moreover,
the positive rates of antibodies specific to 38 F-64 F
for smear-positive, smear-negative, culture-positive or
culture-negative patients were not significantly different.
In smear-negative or culture-negative patients, the posi-
tive rates of antibodies specific to 38 F-64 F were 67.1%
and 69.7%, slightly lower than the positive rates for
smear-positive (75.5%) or culture-positive (70.68%) patients
(Table 2).The diagnostic sensitivities of sputum smear and spu-
tum culture in all of three group TB patients were 38.5%
and 67.1% respectively. The serodiagnostic test using the
novel 38 F-64 F polyprotein significantly improved the
detection rate for the culture-negative or smear-negative
active TB patients. By integration with the serodiagnostic
test, the diagnostic sensitivities to active TB for sputum
smear or sputum culture increased from 38.5% to 79.8%
and from 67.1% to 90.0%, respectively (Figure 2).
Time-course changes in IgG, IgM and IgA antibody titres
after initiation of anti-TB chemotherapy
To assess whether determination of 38 F-64 F specific
antibody responses could be useful for monitoring the
Table 2 Serodiagnosis results of the 38 F-64 F antigens in
the active pulmonary TB patients with different sputum
bacteriology results
Group S + (n = 143) S- (n = 228) C + (n = 249) C- (n = 122)
# Pos. (%) 108 (75.5) 153 (67.1) 176 (70.7) 85 (69.7)
S+: smear-positive active pulmonary TB patients; S-: smear-negative active
pulmonary TB patients; C+: culture-positive active pulmonary TB patients;
C-: culture-negative active pulmonary TB patients; # Pos. (%): number of positive
sera (percentage of positive sera).
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obtained from active TB patients who had undergone
anti-TB chemotherapy for 0–6 months at one month
interval and the serum levels of all of three isotype anti-
bodies, i.e., IgG, IgM and IgA, specific to 38 F-64 F, were
determined. The results are presented as scatter grams
in Figure 3.
In this study, the mean levels of IgG, IgM and IgA
antibodies against 38 F-64 F polyprotein in sera of active
TB patients with different courses of anti-TB chemo-
therapy were shown to be no significant difference when
compared with results from the same patients at their
first visit to the outpatient clinic without anti-TB chemo-
therapy (P > 0.05). The mean antibody levels and the
standard deviation of each groups are shown in Figure 3.
After anti-TB chemotherapy was initiated, the IgG, IgM
and IgA antibody responses were heterogeneous and
differed considerably from patient to patient, although
the response patterns can be categorized into three
types. The antibody levels against 38 F-64 F in some
patients increased with the course of anti-TB chemo-
therapy. In contrast, in some patients, the antibody levels
against 38 F-64 F decreased with the course of anti-TBFigure 2 The positive rates of sputum smear/culture with or
without integration of serodiagnostic test. The integration of
serodiagnostic test with sputum smear or sputum culture increased
the positive rates from 38.54% to 79.78% or from 67.12% to
90.03%, respectively.chemotherapy. The third type of response pattern indi-
cated that the antibody levels against 38 F-64 F were more
stable with slightly fluctuations. Some corresponding ex-
amples are shown in Figure 4.
Discussion
An effective in vitro diagnostic for TB based on serological
methods could be an attractive area of exploration because
immunoassays have advantages of simplicity, rapidity and
low cost, and have possibility to find the cases missed by
standard sputum smear microscopy [2,3,15]. Nevertheless,
considerable progress has been made in the identification
of many new serological antigens in recently years, and
the sensitivity and specificity of serological tests are im-
proving. It is therefore generally accepted that it will be
advantageous to include several antigens in a future sero-
diagnostic assay. In our previous study, the novel polypro-
tein 38 F-64 F including seven Mtb antigens had been
found to achieve higher sensitivity and specificity based
on measuring IgG antibody [13]. The knowledge of the
humoral immune responses at various stages of TB in-
fection and disease could help to elucidate the complex
interaction between host and pathogen [16-18]. A com-
prehensive insight to immunoprofiling of antigen spe-
cific responses is critical not only for the understanding
of disease pathogenesis, but also for development of
diagnostic tests. In view of the heterogeneity of the
humoral response, in this study, serum levels of three
38 F-64 F-specific antibody isotypes, IgG, IgM and IgA,
were evaluated in active TB patients at their first visit to
the outpatient clinic without treatment and those who
had undergone anti-TB treatment.
IgG antibody level is higher in most advanced and ex-
tensive forms of the disease. Patients with active TB usu-
ally exhibited strong IgG responses but poor IgM and
IgA responses [19]. While the function of anti-M. tuber-
culosis antibodies in providing protective immunity is
still under investigation, it has been proposed that they
may be utilized as a diagnostic marker of active disease
[18,19]. Previous studies analyzing IgG antibodies showed
that anti-M. tuberculosis IgG antibodies increased in pa-
tients with active disease [20-22]. In our results, IgG anti-
body level is higher in the most active TB patients with or
without the anti-TB chemotherapy than that in health con-
trol, and the positive rate of IgG was highest among the
three isotypes, indicating that the IgG antibody was the
most extensive antibody isotype.
Usually, IgM antibodies appear first and are produced
in large quantities in response to any antigen and decline
in more advanced phases. Several authors suggested that
IgM antibodies are produced mainly during the early
phase of primary TB infection [23,24]. Therefore, the
IgM-positive patients were diagnosed at an early stage of
the infection process [19,25]. Our results demonstrate
Figure 3 Levels of serum IgG (A), IgM (B) and IgA (C) against the novel 38 F-64 F polyprotein in active TB patients with different
course of chemotherapy. 0 M = patients at their first visit to the outpatient clinic, 1 M-6 M = patients received anti-TB chemotherapy for 1–6
months. The mean antibody level and the standard deviation of each group were shown. There was no significant difference between the
patients at their first visit to the outpatient clinic without anti-TB chemotherapy and those receiving anti-TB chemotherapy for 1–6 months.
All of the p values between each of two groups were greater than 0.05.
Figure 4 Changes in IgG (A1, A2 and A3), IgM (B1, B2 and B3) and IgA (C1, C2 and C3) antibody levels against the novel 38 F-64 F
polyprotein after initiation of anti-TB chemotherapy. After initiation of anti-TB chemotherapy, patients showed three different IgG, IgM and
IgA antibody responses patterns, i.e., decrease, increase and maintaining at stable level.
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isotypes. In China, most people visit a doctor only after
symptoms appear. Accordingly, at their first visit to the
outpatient clinic most TB patients are over the early
stage of the infection process. Interestingly, following
different stages of the infection process, three types of
response patterns of IgM antibody were observed. The
antibody levels of IgM against 38 F-64 F in some pa-
tients became lower with the course of treatment, but
IgM antibody levels in some patients were elevated or
were maintained at more stable levels throughout the
course of anti-TB chemotherapy. Several authors have
observed that IgM antibody production was not associ-
ated with any clinical phases and radiological factor [26].
IgA is secreted during the contact of M. tuberculosis
and/or its antigens with the mucosal surface, which
stimulates the release of cytokines [27]. Several authors
have described the presence of IgA against the mycobac-
terial antigens in the serum of TB patients [26,28-31],
suggesting that this immunoglobulin isotype is present
in both patients with newly acquired infections and
those of a longer duration [32]. In the present investiga-
tion, the positive rate of IgA was not too high in active
TB patients at their first visit to the outpatient clinic and
the IgA antibody levels were maintained for a longer
duration until the completion of anti-TB chemotherapy.
Secondly, from our results, we found that some sera
are IgM- or IgA-positive only. Though most of the active
TB patients (70.4%) could be diagnosed by the detection
of IgG antibody isotype, few TB patients showing IgM-
or IgA-positive only [about 13% (48/371)], were left out,
which would lead to delay in treatment and more exten-
sive transmission of TB. Thus, it should detect different
types of antibodies simultaneously. And in our results,
the test sensitivity was improved for IgG + IgA + IgM
without significantly compromising the specificity. These
results are consistent with the results of Uma Devi et al.
[14]. On the other hand, if one were to test all of three
antibody isotypes, the expense of diagnosis for TB pa-
tient would increase. Therefore, in order to increase the
positive rate and decrease the expense of diagnosis, it
would be necessary for researchers to develop the total
antibody detection method, i.e., double antigen sandwich
ELISA.
The other significant result obtained in this study was
that the positive antibody responses in smear-negative
and/or culture-negative active TB patients were not dif-
ferent significantly with those in smear- and culture-
negative active TB patients. This is in uncoincidence with
some other studies results showing that smear-positive
TB patients generate more proteinaceous antigens than
smear-negative TB patients [33,34]. On the other hand,
there are a few studies showing that the antibody level
does not always correspond to the bacterial load in TBpatients [35,36]. Thus, for serodiagnostic methods, there
is greater value for combination with, not replacement
of, the sputum smear and sputum culture test. The posi-
tive rate would increase in paucibacillary TB patients,
which are difficult to diagnose by bacteriological tests
[12,26]. The findings of Kanaujia GV et al. [9] also dem-
onstrated that the effectiveness of the screening strategy
was improved by integrating multi-antigen ELISA with
microscopic examination of sputum for acid-fast bacilli
in areas with high TB prevalence.
In order to assess whether determination of 38 F-64 F
specific antibody responses could be useful for monitor-
ing the efficacy of chemotherapy, the levels of three iso-
type of antibodies were measured in active TB patients
with different course of anti-TB chemotherapy. On one
hand, the heterogeneity of the antibody response be-
tween patients was confirmed by several researchers in
previous studies [37-39]. We also observed the antibody
response to be heterogeneous in patients with active TB
undergoing anti-TB chemotherapies. On the other hand,
many investigations concerning the changes in anti-
body levels showed that antibody levels decrease after
initiation of anti-TB chemotherapy [40,41]. Our results
did not support such a conclusion. Based on our statis-
tical results, there was no significant difference between
groups with different course of anti-TB chemotherapy
for all of subjects, and the response patterns could be
grouped into three types, i.e. increase, decrease and main-
taining at a stable level. Moreover, the antibody against
Mtb antigen continued to be present throughout the anti-
TB chemotherapy.
A wide spectrum of humoral responses exist in TB pa-
tients, depending on different antigens, the expression
levels of different antigens, the patient’s immunological
background, the disease stage, and/or the type of anti-
TB therapy [42,43]. Although higher sensitivity and spe-
cificity would be obtained based on measuring antibody
against polyprotein, such as 38 F-64 F including seven
proteins from Mtb, the regular change in the level of
antibody against only one antigen would be covered up.
Therefore, the polyprotein may not be suitable for moni-
toring the efficacy of chemotherapy.
Conclusions
Based on our present experiments we can make recom-
mendations that may be helpful in subsequent studies
on the serological diagnosis of TB. First, all of three
38 F-64 F-specific antibody isotypes, IgG, IgM and IgA,
were detected in the sera of TB patients, indicating that
the novel 38 F-64 F polyprotein was suitable for diagnos-
ing active TB and it is necessary to develop the double
antigen sandwich ELISA to detect total antibodies. Sec-
ond, the positive rate would increase in the pauciba-
cillary TB patients by serodiagnostic methods. Thus, an
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multi-antigen ELISA with bacteriology tests in areas with
high TB prevalence. Third, the serodiagnostic test based
on polyprotein antigens does not appear to be useful for
monitoring the efficacy of chemotherapeutics or as a cri-
terion to determine whether the patient should continue
or terminate anti-TB chemotherapy. Therefore, it will be
necessary to evaluate novel predictors of the efficacy of
anti-TB drugs based on other immunological markers,
such as the level of antigen, cytokine, microRNA, alone
or in combination.
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